<DOC>
	<DOCNO>NCT00830336</DOCNO>
	<brief_summary>The study compare relative bioavailability ( rate extent absorption ) 200 mg/5 mL Azithromycin oral suspension manufacture TEVA Pharmaceutical Industries Ltd. ; distribute TEVA Pharmaceuticals USA 200 mg/5 mL ZITHROMAX oral suspension distribute Pfizer lab , division Pfizer Inc. follow single oral 10 mL dose ( 400 mg ) healthy adult subject administer non-fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions</brief_title>
	<detailed_description>Detailed Description Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method Outcome : Confidence interval fell within 80-125 % therefore meet FDA Bioequivalence criterion ; drug relate , serious , unexpected adverse event report study .</detailed_description>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Inclusion Criteria Screening Demographics : All subject select study healthy men woman 18 year age old time dose . The subject 's body mass index ( BMI ) 19 30 . Screening Procedures : Each subject complete screening process within 28 day prior period I dose . Consent document screen evaluation HIV antibody determination review , discuss sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody , hepatitis GB surface antigen , hepatitis C antibody screen URINALYSIS : dipstick ; full microscopic examination dipstick positive URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine SERUM PREGNANCY SCREEN ( female subject ) If female : Of childbearing potential , practice acceptable method birth control duration study judge investigator ( ) , condom spermicide , diaphragm spermicide , intrauterine device ( IUD ) , abstinence ; Is postmenopausal least 1 year ; Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Exclusion Criteria Subjects recent history drug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody HIV antibody . Subjects demonstrate positive drug abuse screen screen study . Female subject demonstrate positive pregnancy screen . Female subject currently breastfeed . Subjects history allergic response ( ) azithromycin relate drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Subjects currently report use tobacco product within 90 day Period I dose administration . Subjects take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Subjects report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . Subjects donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 28 day prior Period I dose . Subjects report take systemic prescription medication 14 day prior Period I dose . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet 28 day prior Period I dose . Female subject report use implant injected hormonal contraceptive ( birth control ) 6 month prior Period I dose . Female subject report use oral hormonal contraceptive ( birth control ) 14 day prior Period I dose . Subjects report difficulty fast consume standardized meal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>